Dermatology Trends 2026: Inflammation Dominates Drug

A recent analysis confirmed what many of us in the field see daily: a staggering 68% of new dermatological drug approvals in 2025 targeted inflammatory skin conditions. This isn’t random. It tells you exactly where the research money is flowing ahead of EADV 2026. For patients, this shift from simply managing symptoms to correcting the underlying immune dysfunction is everything, moving us away from temporary fixes and toward the possibility of long-term remission.

The Inflammatory Imperative: 68% of Approvals Target Inflammation

That 68% of new dermatological drug approvals in 2025 were for inflammatory conditions reflects a deliberate, and frankly long-overdue, scientific pivot. This is the result of decades spent untangling the complex web of immune cells, cytokines, and genetics that drive diseases like psoriasis, atopic dermatitis, and hidradenitis suppurativa. For years, all we really had were topical steroids and blunt immunosuppressants, which came with major side effects and often didn’t work well. The change now is toward sophisticated biologics and small molecule inhibitors that can zero in on a single pathway, like the JAK-STAT or IL-23 pathways, without causing systemic havoc.

Look at the recent approval of an interleukin-23 inhibitor for plaque psoriasis. Phase 3 trial data, published in The New England Journal of Medicine, showed it achieved far superior Psoriasis Area and Severity Index (PASI) 90 response rates compared to older drugs. This represents a genuine leap in our ability to manage these chronic conditions. We’ve moved our focus from just tamping down symptoms to actually changing the course of the disease. My professional opinion is that this approach will only grow, hopefully soon tackling even tougher conditions for patients who have been struggling for years. We are building a future where sustained remission becomes the standard of care for a wider range of inflammatory dermatoses.

Personalized Dermatology: A Market Set to Hit $18.5 Billion by 2028

The market for personalized dermatology solutions is on track to hit $18.5 billion by 2028. This growth is being driven by a confluence of powerful tech: cheaper genomic sequencing, AI-powered diagnostics, and better biomarker discovery. We’re on the cusp of a time where a simple genetic test can tell us which biologic will work best for a patient’s atopic dermatitis, or an AI can analyze a slide and tell me the exact active ingredients to prescribe for their specific type of acne. A report from Grand View Research confirms this explosive growth, and from my perspective, it’s about a fundamental shift in patient and practitioner expectations.

It’s not just about prescriptions, either. We’re already seeing a boom in custom-compounded topicals that are formulated based on a patient’s unique skin microbiome analysis, and even diagnostic tools that guide cosmetic procedures by assessing specific protein expressions. The era of standardized, one-size-fits-all skincare protocols is ending. In the clinic, this means we’re shifting from reacting to flare-ups to proactively predicting them based on an individual’s biological signature. For the patient, this means we can stop the frustrating cycle of trying three different creams before finding one that works. The big question, of course, is cost. Who is going to pay for these advanced diagnostics, and how do we prevent a two-tiered system of care from developing?

AI Integration Lag: Only 15% of Practices Fully Integrated

As of early 2026, only 15% of dermatology practices globally have fully integrated artificial intelligence tools for diagnostics and treatment planning. I’ll be honest, that number is surprisingly low. The algorithms for analyzing dermoscopic images are already here, some performing as well as or even better than a seasoned dermatologist at spotting melanoma. We’re seeing platforms like PathAI do incredible things in pathology, so the slow uptake in the clinic is a bit of a head-scratcher.

The reasons are complicated. You have the upfront cost and the time it takes to train staff, plus real concerns around data privacy and regulations. And let’s be real, there’s also the human factor. Many practitioners are just resistant to handing over diagnostic authority to an algorithm, no matter how much data it can process. This 15% adoption rate is a real problem because it’s holding back patient care. The clinics that figure this out first will be able to screen patients faster and more accurately, catching things like early-stage melanomas that might otherwise be missed. That is a tangible benefit that can’t be overstated.

Engagement Drives Adherence: 30% Increase with Biometric Platforms

Getting patients with chronic conditions to stick to their treatment plan is one of the hardest parts of the job. For years, “patient engagement” just meant nagging them with reminder calls. But now we have solid data from a multi-center study showing that patient engagement platforms using real-time biometric data can boost treatment adherence by 30%. For something like psoriasis or severe acne where daily consistency is everything, that’s huge. These are smartphone apps that let patients log their symptoms and medication use, but also track things like local humidity or UV exposure, and then get smart feedback.

The “real-time biometric data” is the secret sauce here. This is far more sophisticated than a simple digital diary. It’s about using data from wearables that track things like skin hydration or temperature to give objective feedback to both the patient and the doctor. For instance, a patient with atopic dermatitis might get a notification on their phone if their skin hydration drops, prompting them to moisturize. That simple alert, triggered by objective data, teaches the patient to connect an environmental factor with a necessary action, reinforcing the behavior far better than a brochure ever could. It fundamentally changes the doctor-patient relationship from a few 15-minute appointments a year to a continuous partnership, a model that, as a paper in the Journal of the American Academy of Dermatology confirms, actually moves the needle on long-term outcomes.

A Point of Contention: The Long-Term Safety of Novel Biologics

Here’s where I have to be the voice of caution amidst all the optimism: 45% of surveyed dermatologists have concerns about the long-term safety of these new biologics and small molecule inhibitors. Though their efficacy is often astounding, these therapies are still very new. The clinical trial data we have is solid for the short and medium term, certainly. But what happens after 10, 15, or 20 years of continuous use? We just don’t know yet. These are powerful medications that fundamentally alter immune pathways, which comes with risks. An editorial in The Lancet recently touched on this very point, arguing for much more extensive post-market surveillance.

It’s easy to get swept up in the undeniable benefits these drugs offer. But as a practitioner, my job is to think about the long game. We have to wonder about the increased risk of certain infections after a decade of use, or the potential for malignancies that might take years to show up. These are the critical questions we must ask as we start prescribing these powerful medications to younger patients for lifelong conditions. My position is simple: we should absolutely embrace these new tools, but with our eyes wide open, demanding rigorous, long-term post-market surveillance to ensure patient safety remains our top priority, always.

These are the conversations that will dominate EADV 2026. We’re seeing a fundamental shift in how we approach patient care, with more precise and personalized solutions for the most complex conditions becoming a reality. For more on how to prepare your skin for various treatments, check out our insights on waxing prep skincare strategy or how painless waxing offers skin health tips.